

Second ICOD Symposium

Innovative therapeutic approaches for cognitive impairment in Down syndrome

In occasion of the World Down syndrome Day (21st of march 2023)

Madrid, March 21st 2023
Hospital Universitario de la Princesa
Madrid, Spain



The ICOD project has received the funding from the European Union's Horizon research and innovation programme under grant agreement n° 899986

International Scientific Committee

Diego Real De Asúa (Madrid)

Fernando Moldenhauer (Madrid)

Filippo Caraci (Catania-Troina)

Mara Dierssen (Barcelona)

Rafael De La Torre (Barcelona)

Ana Maria Aldea (Barcelona)

Beatriz Fagundo (Barcelona)

Stephanie Monlezun (Bordeaux)

Pier Vincenzo Piazza (Bordeaux)

Sophie Durand (Paris)

Renaud Touraine (Saint Étienne)

Local Scientific Committee

Eleonore Venin, Lorenzo Mercadante

Rationale

The **ICOD project** (Improving COgnition in Down syndrome), funded by European Union, **aims to improve the cognitive impairment of individuals with Down syndrome with AEF0217**, a first-in-class new pharmacological treatment developed by the french Biotech Aelis Farma, and specifically designed to this end. The project was launched in February 2021 and a first ICOD symposium was held in Troina, Italy, on the occasion of the World Down syndrome Day 2022 with a strong participation of DS families.

The second ICOD symposium will take place in **Madrid** in 2023 at Hospital Universitario de la Princesa on the World Down syndrome Day (March 21st). The symposium will be specifically dedicated to **increase the knowledge about innovative therapeutic approaches to cognitive deficits in DS and promote the involvement of adults with DS in research**. Face-to-face interaction and active discussions between families, associations of individuals with Down syndrome and researchers involved in the ICOD project will be promoted, as well as with other researchers working in the field of Down syndrome.

This event will be **designed in close cooperation with the European Down syndrome Association (EDSA) and associations of each participating European country in the ICOD project**; in particular with Spanish Down syndrome organizations (Down España, Fundación Down Madrid, Down Catalunya, Fundació Catalana síndrome de Down among others), Federation Trisomie 21 France, Association Française pour la Recherche sur la Trisomie 21, Italian Down syndrome organizations (AIPD and Cooldown) and the Italian Task Force for DS.

Monday March 20th 2023

14:00h - 18:00h

Pre-symposium: the third F2F meeting of the ICOD project

The European consortium is led by IMIM (Rafael de la Torre, Barcelona, Spain) and AELIS FARMA (Stephanie Monlezun & Pier Vincenzo Piazza, Bordeaux, France) in collaboration with Oasi Research Institute (Filippo Caraci, UniCT, Catania & Oasi Troina, Italy), Institut Jérôme Lejeune (Sophie Durand, Paris, France), Centre Hospitalier Universitaire (Renaud Touraine, Saint-Etienne, France) and Hospital Universitario de la Princesa (Fernando Moldenhauer and Diego Real de Asúa, SERMAS, Madrid, Spain).

Tuesday March 21st, 2023

15:00h - 15:10h

Institutional greetings and introduction to the ICOD symposium

Fernando Moldenhauer (Spain)

15:10h - 15:30h

Opening lecture

Down syndrome research in the framework of European Union

Monica Ensini, European Commission

Session 1: Scientific advances in understanding cognitive dysfunction in Down syndrome

Introduced and moderated by Mara Dierssen & Diego Real de Asúa (Spain)

15:30h - 15:50h

Neurobiology of cognitive dysfunction in DS: novel treatment targets

Eugenio Barone (Italy)

15:50h - 16:30h

AEF0217: an innovative drug for the treatment of cognitive dysfunction in DS

Pier Vincenzo Piazza, CEO Aelis Farma (France)

16:30h - 17:00h / Break

Session 2: FAMILY FORUM - New strategies for the treatment of cognitive deficits in DS

Introduced and moderated by Sophie Durand (France)

17:00h - 17:30h

The ICOD project: what will it bring to families? Phase I and Phase II studies

Rafael De La Torre (Spain) & Filippo Caraci (Catania, Troina)

17:30h - 18:15h

The ICOD project: a research centered on Down syndrome individuals

- New tools for informing individuals with Down syndrome about clinical studies
Beatriz Fagundo (Spain)

- Evaluating cognitive deficits in DS: what we have learned from the NIUS Study
Beatriz Fagundo (Spain)

- Evaluation of drug effects on individuals with Down syndrome: the PICTEA project
Patricia Diaz Pellicer (Spain)

Tuesday March 21st, 2023

18:15h - 18:45h

**Discussion with families and
associations: expectations on therapies
for cognitive deficits**

Introduced and moderated by Marzia Perluigi (Italy)
& Renaud Touraine (France)

- Expectations about therapy for cognitive deficits: what they know and what they expect
- Treatment of cognitive deficits in adults over 35?
- Timing of therapies for DS: when, what, how long

18:45h - 19:15h

**Discussion with families and
associations: Involvement of adults with
DS in research, ensuring ethical and
safety aspects**

Introduced and moderated by Fernando Moldenhauer (Madrid)

19:15h - 19:30h

Concluding remarks

Rafael De La Torre (Spain)

